September 1, 2026
NV Therapeutics welcomes Dr. Caroline Kuo as Scientific Advisor.

NV Therapeutics is pleased to welcome Caroline Kuo, M.D., as a Scientific Advisor.

Dr. Kuo is a physician-scientist and Assistant Professor of Pediatrics at the University of California, Los Angeles (UCLA), specializing in primary immune deficiencies and the development of gene therapies for inherited immune disorders. Her clinical and translational research focuses on hematopoietic stem cell gene therapy, with extensive experience advancing novel therapeutic approaches for rare genetic diseases. Dr. Kuo will advise NV Therapeutics as the company advances its non-viral gene writing platform and therapeutic programs.

August 10, 2026
NV Therapeutics welcomes Dr. Agnieszka Czechowicz as Scientific Advisor.

NV Therapeutics is pleased to welcome Agnieszka Czechowicz, M.D., Ph.D. as a Scientific Advisor.

Dr. Czechowicz is a physician-scientist, entrepreneur, and Assistant Professor of Pediatrics at Stanford University, where her research focuses on hematopoietic stem cell biology, transplantation, gene therapy and gene editing. A pioneer in targeted, non-genotoxic approaches to stem cell transplantation, her work has helped advance new strategies for conditioning and the treatment of genetic blood and immune disorders. Dr. Czechowicz will advise NV Therapeutics as the company advances its non-viral gene writing platform and therapeutic programs.

June 8, 2026
NV Therapeutics featured in San Francisco Business Times for pioneering patient-centered gene therapy development

The San Francisco Business Times today featured NV Therapeutics and its Patient-in-Residence and Advisor, Jimi Olaghere, highlighting the company’s commitment to integrating patient perspectives into the earliest stages of therapeutic development. Drawing on Jimi’s experience as a recipient of CRISPR-based gene therapy for Sickle Cell Disease, the article explores how meaningful patient engagement can help shape the development of more effective, accessible, and affordable advanced therapies.

Read the San Francisco Business Times feature → (Complimentary access) 

January 28, 2026
NV Therapeutics welcomes Jimi Olaghere as Patient-in-Residence & Advisor

NV Therapeutics has appointed Jimi Olaghere, a Casgevy CRISPR gene therapy recipient, as Patient-in-Residence and Advisor for Q1 2026. This initiative embeds the lived patient experience directly into the R&D phase, ensuring the company’s strategic trajectory is driven by the specific needs of the people for whom gene therapies are engineered, while advancing a core mission of improving global access and health equity.

September 12, 2025
NV Therapeutics signs Sponsored Research Agreement with University College London

NV Therapeutics, Inc. has signed a Sponsored Research Agreement with University College London in order to formalize collaborative research projects with the laboratories of Adrian Thrasher, M.D., Ph.D., Physician and Professor of Pediatric Hematology and Giorgia Santilli, Ph.D., Professor in Gene Therapy at University College London Great Ormond Street Institute of Child Health (GOSH) in London, the United Kingdom.

July 29, 2025
NV Therapeutics signs Sponsored Research Agreement with UCLA

NV Therapeutics, Inc. has signed a Sponsored Research Agreement with the University of California, Los Angeles in order to formalize collaborative research projects with the laboratories of Donald Kohn, M.D., Physician and Distinguished Professor of Pediatric Hematology and Oncology and Caroline Kuo, M.D.., Physician and Assistant Professor of Pediatrics at the David Geffen School of Medicine and Broad Stem Cell Research Center, University of California, Los Angeles.

October 7, 2024
NV Therapeutics begins operations at Bakar BioLabs incubator

NV Therapeutics, Inc. has established laboratory operations at Bakar BioLabs, a world-class incubator site for life science startups in Berkeley, California. Founded as a partnership between University of California, Berkeley and QB3, the incubator provides a supportive ecosystem for NV Therapeutics to develop their platform technology and therapeutic programs.

September 13, 2024
NV Therapeutics secures Seed Funding from 4BIO Capital

Seed Funding from 4BIO Capital (4BIO Partners LLP), a London, United Kingdom based venture capital firm specializing in early-stage life sciences and advanced therapies, enables NV Therapeutics, Inc. to establish business operations and execute its recruitment and facility build plan.